Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN

Regeneron Pharmaceuticals, Inc. financial statements

Regeneron Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue14.3B14.2B13.1B12.2B16.1B8.50B6.56B5.15B5.87B4.86B
Cost of revenue402.8M237.5M202.5M194.6M
Gross profit6.15B4.91B5.67B4.67B
Research and development5.85B5.13B4.44B3.59B2.86B2.65B2.45B1.47B2.08B2.05B
Selling, general and administrative2.70B2.95B2.63B2.12B1.82B1.35B1.34B1.13B1.32B1.18B
Operating income3.58B3.99B4.05B4.74B8.95B3.58B2.21B2.53B2.08B1.33B
Depreciation and amortization543.7M482.9M421.0M341.4M286.2M235.9M210.3M148.2M145.5M104.7M
EBITDA4.12B4.47B4.47B5.08B9.23B3.81B2.42B2.68B2.23B1.44B
Interest expense43.8M55.2M73.0M59.4M57.3M56.9M30.2M28.2M25.1M7.20M
Income before tax5.23B4.78B4.20B4.86B9.33B3.81B2.43B2.55B2.08B1.33B
Income tax725.8M367.3M245.7M520.4M1.25B297.2M313.3M109.1M880.0M434.3M
Net income4.50B4.41B3.95B4.34B8.08B3.51B2.12B2.44B1.20B895.5M
Earnings per share, basic43.0740.9037.0540.5176.4032.6519.3822.6511.278.55
Earnings per share, diluted41.4838.3434.7738.2271.9730.5218.4621.2910.347.70

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.12B2.49B2.73B3.11B2.89B2.19B1.62B1.47B812.7M535.2M
Short-term investments5.49B6.52B8.11B4.64B2.81B1.39B1.60B1.34B596.8M503.5M
Receivables5.74B6.21B5.67B5.33B6.04B4.11B2.10B1.72B1.54B1.34B
Inventory3.20B3.09B2.58B2.40B1.95B1.92B1.42B1.15B726.1M399.4M
Current assets18.0B18.7B19.5B15.9B14.0B9.78B7.69B6.45B4.33B3.18B
Property, plant and equipment3.48B3.22B2.89B2.58B2.36B2.08B
Total assets40.6B37.8B33.1B29.2B25.4B17.2B14.8B11.7B8.76B6.97B
Accounts payable939.0M789.5M606.6M589.2M564.0M475.5M418.1M218.2M178.2M
Current liabilities4.37B3.94B3.42B3.14B3.93B2.70B2.10B1.44B1.14B1.24B
Long-term debt1.99B1.98B1.98B1.98B1.98B1.98B0
Total debt1.99B1.98B1.98B1.98B1.98B1.98B0
Total liabilities9.30B8.41B7.11B6.55B6.67B6.14B3.72B2.98B2.62B2.52B
Shareholders' equity31.3B29.4B26.0B22.7B18.8B11.0B11.1B8.76B6.14B4.45B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations4.98B4.42B4.59B5.01B7.08B2.62B2.43B2.20B1.31B1.49B
Capital spending-898.4M-755.9M-718.6M-590.1M-551.9M-614.6M-429.6M-383.1M-272.6M-511.9M
Free cash flow4.08B3.66B3.88B4.42B6.53B2.00B2.00B1.81B1.03B974.0M
Cash from investing-629.1M-2.47B-3.19B-3.78B-5.38B-70.6M-2.03B-1.46B-1.01B-1.05B
Cash from financing-3.72B-2.20B-1.79B-1.01B-1.01B-1.97B-252.1M-77.1M-24.4M-700.5M
Dividends paid-370.3M00
Share buybacks-3.44B-2.60B-2.23B-2.08B-1.65B-5.85B-275.9M-4.40M00
Change in cash634.7M-248.8M-381.6M221.3M690.8M577.0M150.1M655.0M277.5M-261.4M